Page 6 - Astrazeneca

Govt caps maximum price of Covishield, Covaxin, Sputnik V for pvt hospitals

The govt has set the maximum price private hospitals can charge for the three Covid vaccines currently available in the country -- Covishield Rs 780 per dose, Covaxin Rs 1,410, and Sputnik V Rs 1,145

India Coronavirus Dispatch: Daily infections retreat to 61-day low

Centre 'willing' to rethink vaccine procurement policy, six UP districts among those with the lowest vaccination coverage, and more-news relevant to India's fight against the pandemic

US will share a 'substantial' number of Covid-19 vaccine doses with India

Exact number yet to be frozen; first tranche of 25 mn shots earmarked from Asia, LatAm, Africa

Japan enters Taiwan-China fight with Covid-19 vaccine shipments to Taipei

Donating the vaccines to Taiwan could irritate China, Japan's biggest trading partner.

AstraZeneca vax 2nd dose FAQs about blood clots, safety, risks and symptoms

Rare but serious blood clots that have been linked the AstraZeneca Covid-19 vaccine have many people especially those who have already had one dose of the vaccine looking for information

European Union takes on AstraZeneca in court over vaccine deliveries

The long-standing dispute drew media attention for weeks earlier this year amid a deadly surge of coronavirus infections in Europe

AstraZeneca Pharma India Q4 net profit up nearly 3-fold to Rs 27.27 cr

Drug firm AstraZeneca Pharma India on Tuesday reported a nearly three-fold jump in its net profit to Rs 27.27 crore for the quarter ended March 31, 2021. The company had posted a net profit of Rs 9.57 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing. Revenue from operations of the company stood at Rs 210.25 crore for the quarter under consideration. It was Rs 194.90 crore for the same period a year ago, it added. For the financial year ended March this year, the net profit of the company was Rs 93.30 crore as against Rs 72.22 crore for the previous financial year, the filing said. The company's revenue from operations stood at Rs 813.56 crore for the financial year ended March 31, 2021. It was Rs 831.80 crore for the year-ago fiscal, it added. Shares of AstraZeneca Pharma India closed at Rs 3,862.45 per scrip on BSE, up 0.84 percent from its previous close.

Delhi yet to receive more Covid-19 vaccines for 18-44 group, says Atishi

Delhi is yet to receive more vaccines for the 18-44 age group and only private hospitals are giving jabs to beneficiaries in this category for now, Aam Aadmi Party MLA Atishi said on Tuesday

Covid-19 vaccines are all highly protective against death, study shows

Efficacy against Covid-linked disease averaged about 85% after a full course, say University of Florida researchers.

Two doses of AstraZeneca vaccine 85-90% effective: Public Health England

Two doses of the Oxford/AstraZeneca vaccine are around 85 per cent to 90 per cent effective against symptomatic disease, Public Health England (PHE) has said

How some vaccines are helping nations to exit Covid faster than others

Messenger RNA shots developed by Moderna or Pfizer and BioNTech are better at stopping people from becoming contagious, shows evidence.

The way forward for firms

Indian firms need to prepare for export boom by vaccinating employees, their family members; and prioritise export market

Norway excludes AstraZeneca from vaccination campaign, says PM Erna Solberg

Norway has removed the vaccine against Covid-19 made by AstraZeneca from its inoculation campaign, Prime Minister Erna Solberg said.

Canadian province halts AstraZeneca first doses over blood clot concerns

Canada's largest province said Tuesday it will stop giving out first doses of the Oxford-AstraZeneca coronavirus vaccine due to concerns over its link to rare blood clots

European Union insists dispute with AstraZeneca is only contractual

The European Commission insisted Monday it still trusts the coronavirus vaccine developed by AstraZeneca and that its dispute with the Anglo-Swedish drugmaker is only contractual

Covid-19 vaccination: Germany allows J&J, AstraZeneca jabs for all adults

Germany is making the one-shot Johnson & Johnson coronavirus vaccine available to all adults as it did with the AstraZeneca vaccine, though the bulk of the expected deliveries is still some way off. Germany has recommended the AstraZeneca shot mainly for over-60s because of a rare type of blood clot seen in an extremely small number of recipients. But amid a push to get as many people inoculated as possible, the government decided to allow doctors' offices to vaccinate any adults with it -- putting aside a priority system under which the oldest and most vulnerable have been vaccinated first. Health Minister Jens Spahn said authorities decided Monday to take the same approach with the Johnson & Johnson vaccine, about which there are similar concerns. He estimated that 5 to 6 million over-60s in Germany still need to be vaccinated and that should be concluded by early June. Spahn said the largest deliveries from Johnson & Johnson, more than 10 million doses, are expected in .

After just Rs 18,000 cr profits in a decade, Serum, Bharat Biotech may earn big with Covid

For both companies, the pandemic presents a once-in-a-lifetime opportunity to earn hundreds of crores of rupees that could be ploughed back to fund further research and capacity expansion

Covid-19: European Union doesn't renew the order for AstraZeneca vaccine

The EU Commission did not renew its order for AstraZeneca's Covid-19 vaccine, the European Union's Internal Market Commissioner said

Gap between AstraZeneca doses can be as little as 4 weeks: Germany

Germany defends AstraZeneca pivot as key to speeding Covid vaccinations; experts warn on reduced efficacy with shorter gap

Jesse Jackson urges Biden to release AstraZeneca vaccine doeses for India

At a news conference in Chicago, American civil rights activist Rev Jesse Jackson said he would speak to Biden to immediately release 60 million doses of AstraZeneca vaccines to India